Trial Search Results

Aromatase Inhibitor Growth Study: Letrozole vs. Anastrozole

The purpose of the study is to determine if there are differences in the final height or hormone profile of short pubertal boys placed on different forms of aromatase inhibitor now routinely used to increase stature: Anastrozole and Letrozole. It also should determine if there are differences in the side effect profiles of the two drugs to be used.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University

Stanford Investigator(s):


  • Drug: Letrozole
  • Drug: Anastrozole


Phase 4


Inclusion Criteria:

   - Current height less than 5th percentile AND/OR

   - Predicted adult height (based on bone age) more than 10 cm below target height (mid
   parental height)

   - Evidence of puberty: physical signs and serum luteinizing hormone > 0.3 IU/L and
   testosterone > 15 ng/dl

Exclusion Criteria:

   - Bone age reading more than 14.0 years

   - Follicle stimulating hormone > 20 IU/L

Ages Eligible for Study

10 Years - 17 Years

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
E Kirk Neely, MD